RxDoctor Payments Data

Michael Brodsky, MD

Clinical Cardiac Electrophysiology · Santa Ana, CANPI 1275538423

Payments from drug & device makers

$167,435in general payments, 2019–2025

Across 416 payments — averaging $402.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$90K
  • Janssen Research & Development, LLC$48K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$17K
  • Biotronik Inc.$3K
  • Abbott$3K
  • Boston Scientific$1K
  • plus $5K from 17 others

What the payments were for

  • Consulting fees$3000%
  • Speaking & faculty fees$90,80576%
  • Travel & lodging$9,6088%
  • Food & beverage$19,22116%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$167,435 in reported general payments places this provider in the 75th percentile of 290 clinical cardiac electrophysiology providers in California.

See all clinical cardiac electrophysiology providers in California

Medicare billing

Part B allowed, 2024
$60,429
Medicare patients
328
Services billed
714

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban274$283,694
EliquisApixaban150$178,880
EntrestoSacubitril/Valsartan54$66,542
JardianceEmpagliflozin11$15,710
Metoprolol Succinate471$7,900
Midodrine Hcl31$3,522
Digoxin144$3,292
Atorvastatin Calcium147$2,860
Amlodipine Besylate199$2,269
Carvedilol ErCarvedilol Phosphate12$2,134
Flecainide Acetate44$1,951
Losartan Potassium163$1,949
Isosorbide Dinitrate31$1,938
Hydralazine Hcl133$1,598
Amiodarone Hcl101$1,504

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$90,147$283,694274 claims
NovartisEntresto$364$66,54254 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 290 clinical cardiac electrophysiology providers in California.

Other clinical cardiac electrophysiology in Santa Ana

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →